GW PHARMACEUTICALS PLC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Sep 30, 2018
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange loss
Stock-based compensation
Depreciation and amortization
Deferred income taxes
Gain from sale of priority review voucher
Other
Changes in operating assets and liabilities:
Accounts receivable, net
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Current tax liabilities
Accrued liabilities
Other current liabilities
Long-term liabilities
Other liabilities
Net cash used in operating activities
Cash flows from investing activities
Proceeds from sale of priority review voucher
Additions to property, plant and equipment
Additions to capitalized software
Additions to intangible assets - licenses
Proceeds from disposal of property, plant and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities
Proceeds from issuance of ordinary shares, net of issuance costs
Proceeds from exercise of stock options
Payments on build-to-suit financing obligation
Payments on capital leases
Payments in connection with common stock withheld for employee tax obligation
Payments on finance leases
Payments on landlord financing obligation
Net cash (used in) provided by financing activities
Effect of exchange rate changes on cash
Effect of exchange rate changes on cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Income taxes paid
Interest paid
Supplemental disclosure of noncash information:
Property and equipment purchases in accounts payable and accrued liabilities

Comments